Evidence map›Paper›PMID 39911853›Full record

ArticleOncoscience2025

Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.

Areti Kalfoutzou, Kalliroi Spanou, Adam Mylonakis, Vassiliki Lagopoulou, Maria Dimitrakoudi, Alexandra Korovila, Christos Piperis, Eleni Tsiouri, Eleni Mostratou

Abstract readCase Reports
In one paragraph

Article in Oncoscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Management of skeletal-related events and fracture prevention in systemic mastocytosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Areti KalfoutzouDepartment of Medical Oncology, 251 Air Force General Hospital, Athens 115 25, Greece.
Kalliroi SpanouDepartment of Pathology, 251 Air Force General Hospital, Athens 115 25, Greece.
Adam MylonakisFirst Department of Surgery, "Laiko" General Hospital, National and Kapodistrian University of Athens 115 27, Greece.
Vassiliki LagopoulouDepartment of Pathology, 251 Air Force General Hospital, Athens 115 25, Greece.
Maria DimitrakoudiDepartment of Hematology, "Laiko" General Hospital, National and Kapodistrian University of Athens 115 27, Greece.
Alexandra KorovilaDepartment of Radiation Oncology, Alexandra Regional General Hospital, Athens 115 28, Greece.
Christos PiperisDepartment of Cardiology, "Georgios Gennimatas" General Hospital, Athens 115 27, Greece.
Eleni TsiouriSecond Department of Internal Medicine, 251 Air Force General Hospital, Athens 115 25, Greece.
Eleni MostratouSecond Department of Internal Medicine, 251 Air Force General Hospital, Athens 115 25, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic mastocytosis (SM) encompasses a wide spectrum of myeloproliferative disorders defined by the aggregation of abnormal mast cells in various tissues, including the bone marrow, gastrointestinal tract, liver and lymph nodes. The release of tryptase, interleukins and cytokines by the accumulated mast cells causes a multi-system response that can range from mild flushing and pruritus to severe anaphylactic reactions, gastrointestinal disturbances, and cardiovascular symptoms, including hypotension and syncope. Furthermore, severe osteoporosis manifesting as bone-lytic lesions or pathologic fractures due to mast cell mediator-triggered bone resorption, is a rather common manifestation of SM, occurring in more than two-thirds of patients. The vast majority of SM cases harbor the D816V KIT mutation, which is an independent prognostic factor, and serves as a therapeutic target. This is a rare case of a young male who presented with new-onset back pain due to osteoporotic fractures and was diagnosed with SM without the D816V KIT mutation. Our case aims to emphasize one of the most underrecognised causes of osteoporosis in adults, and to shed light on a frequently misdiagnosed yet potentially severe hematologic disorder.

Indexed as

anaphylaxismast cellsmastocytosisosteoporosis

Identifiers

PMID39911853
PMCPMC11796133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.